VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76,470 | +2.1% | 1,500 | 0.0% | 0.01% | +10.0% |
| Q2 2023 | $74,910 | +33.2% | 1,500 | 0.0% | 0.01% | +42.9% |
| Q1 2023 | $56,220 | -21.8% | 1,500 | 0.0% | 0.01% | -36.4% |
| Q4 2022 | $71,925 | +99.8% | 1,500 | 0.0% | 0.01% | +83.3% |
| Q3 2022 | $36,000 | +9.1% | 1,500 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $33,000 | -8.3% | 1,500 | 0.0% | 0.01% | +20.0% |
| Q1 2022 | $36,000 | 0.0% | 1,500 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $36,000 | -5.3% | 1,500 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $38,000 | – | 1,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $110,721,000 | 37.88% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $50,150,000 | 29.14% |
| Pivotal bioVenture Partners Investment Advisor LLC | 2,222,970 | $59,064,000 | 19.47% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $61,365,000 | 4.73% |
| TPG Group Holdings (SBS) Advisors, Inc. | 4,941,213 | $131,288,000 | 1.46% |
| RA Capital Management | 3,710,699 | $98,593,000 | 1.38% |
| Foresite Capital Management IV, LLC | 465,821 | $12,377,000 | 1.34% |
| Opaleye Management Inc. | 335,200 | $8,906,000 | 1.16% |
| Novo Holdings A/S | 416,937 | $11,078,000 | 0.48% |
| Affinity Asset Advisors, LLC | 30,000 | $797,000 | 0.42% |